EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Protein Kinase CK2 Inhibition Represents a Pharmacological Chance for the Treatment of Skin Diseases

Michele Scuruchi iD, Desirèe Speranza iD, Giuseppe Bruschetta iD, Federico Vaccaro, Mariarosaria Galeano, Giovanni Pallio iD, Mario Vaccaro iD, Francesco Borgia iD, Federica Li Pomi iD, Massimo Collino iD, Natasha Irrera

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26115404 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Michele Scuruchi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy. Hauptthemen laut MEDLINE: Casein Kinase II, Protein Kinase Inhibitors, Skin Diseases. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Protein kinase CK2 has emerged as a pivotal regulator of cellular processes involved in skin homeostasis, including cell proliferation, differentiation and inflammatory response regulation. In fact, CK2 activity dysregulation is implicated in the pathogenesis of different skin diseases, such as psoriasis, cancer and inflammatory dermatoses. CK2 overactivation fosters keratinocyte proliferation and pro-inflammatory cytokine production through the STAT3 and Akt pathways in psoriasis, thus contributing to epidermal hyperplasia and inflammation. In the realm of oncology, CK2 overexpression correlates with tumor progression, facilitating cell survival and metastasis in melanoma and non-melanoma skin cancers. Pharmacological inhibition of CK2 has demonstrated therapeutic potential, with CX-4945 (Silmitasertib) as the most studied adenosine triphosphate-competitive inhibitor (ATP-competitive inhibitor). Preclinical models reveal that CK2 inhibitors effectively mitigate pathological features of psoriasis, regulate keratinocyte differentiation, and suppress tumor growth in skin cancers. These inhibitors also potentiate the efficacy of conventional chemotherapeutics and exhibit anti-inflammatory effects in dermatological conditions. Future research will aim to enhance the specificity and delivery of CK2-targeting therapies, including topical formulations, to minimize systemic side effects. Combination therapies integrating CK2 inhibitors with other agents might offer synergistic benefits in managing skin diseases. This review underscores CK2’s critical role in skin and its therapeutic potential as a pharmacological target, advocating for innovative approaches to harness CK2 inhibition in dermatology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Casein Kinase IIProtein Kinase InhibitorsSkin DiseasesHumansAnimalsSkin NeoplasmsPsoriasisKeratinocytesNaphthyridinesPhenazines

Stichwörter der Autor:innen

CK2 kinasecancerinflammationskin

Substanzen

Casein Kinase IIProtein Kinase InhibitorssilmitasertibNaphthyridinesPhenazines

Autor:innen und Institutionen

  • Department of Clinical and Experimental Medicine, University of Messina, Via C. Valeria, 98125 Messina, Italy.
  • Department of Veterinary Sciences, University of Messina, Viale G. Palatucci, 98168 Messina, Italy.
  • Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina, Via C. Valeria, 98125 Messina, Italy.
  • Department of Neurosciences "Rita Levi Montalcini", University of Torino, Via Verdi, 10124 Torino, Italy.

ORCID-Profile: Michele Scuruchi, Desirèe Speranza, Giuseppe Bruschetta, Giovanni Pallio, Mario Vaccaro, Francesco Borgia, Federica Li Pomi, Massimo Collino

Zitieren

APA

Scuruchi, M., Speranza, D., Bruschetta, G., Vaccaro, F., Galeano, M., Pallio, G., Vaccaro, M., Borgia, F., Li Pomi, F., Collino, M., & Irrera, N. (2025). Protein Kinase CK2 Inhibition Represents a Pharmacological Chance for the Treatment of Skin Diseases. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26115404

Vancouver

Scuruchi M, Speranza D, Bruschetta G, Vaccaro F, Galeano M, Pallio G, et al. Protein Kinase CK2 Inhibition Represents a Pharmacological Chance for the Treatment of Skin Diseases. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26115404

BibTeX
@article{Scuruchi2025,
  author = {Scuruchi, Michele and Speranza, Desirèe and Bruschetta, Giuseppe and Vaccaro, Federico and Galeano, Mariarosaria and Pallio, Giovanni and Vaccaro, Mario and Borgia, Francesco and Li Pomi, Federica and Collino, Massimo and Irrera, Natasha},
  title = {Protein Kinase CK2 Inhibition Represents a Pharmacological Chance for the Treatment of Skin Diseases},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26115404}
}
Kostenlos starten →